Efifcacy and safety of lidocaine cataplasms 5%for the treatment of post-herpetic neuralgia
王爱平,王晓雯,赵俊英,葛蒙梁,郭在培,宋智琦,白彦萍,韩秀萍,杨雪源,李明,陆前进,鲁建云,顾军,谢红付,陈涛,郑捷,邱双军,丁娜,李若瑜
DOI: https://doi.org/10.11786/sypfbxzz.1674-1293.20150306
2015-01-01
Abstract:Objective To compare efifcacy and safety of lidocaine cataplasms 5% with placebo cataplasms treatment in patients with post-herpetic neuralgia(PHN). Methods The design of this trial was a central-randomized, double-blind, vehicle-controlled, parallel group, multicenter study. The most painful area had to be coverable by up to three cataplasms in patients with PHN. The cataplasms had to be applied to the area of maximal pain for up to 12 hours within each 24-hour period for 4 weeks. Results To evaluate the primary outcome at 4 weeks, pain relief was measured with VAS compared with baseline in patients’ diaries. Results showed good pain relief, which was associated with a reduction of (20.71±19.07)mm for lidocaine cataplasms 5% group, compared with placebo cataplasms group (8.04±14.25)mm (P<0.0001). At 4 weeks, a reduction of VAS of at least 30% was achieved in 56.07% and 20.39% (P<0.0001), respectively, a reduction of VAS of at least 50% was observed in 36.45% and 11.65% (P<0.0001), respectively. The early withdraw rates were 1.68% and 7.83% (P=0.0264), respectively. Drug-related adverse events occurred in 10.83% of the lidocaine cataplasms 5% group, and 12.93% of the placebo cataplasms group (P=0.6183), mainly as localized skin reactions, incidences rates were 5% and 6.03% (P =0.7277), respectively. Conclusion Lidocaine cataplasms 5% therapy provides signiifcant efifcacy compared with placebo cataplasms, and is a well-tolerated, safe and convenient treatment option for PHN patients.